Company Overview

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

  • Name

    WuXi AppTec Co., Ltd.

  • CEO

    Dr. Ge Li Ph.D.

  • Website

    www.wuxiapptec.com

  • Sector

    Life Sciences Tools and Services

  • Year Founded

    2000

Profile

  • Market Cap

    CN¥110.14B

  • EV

    CN¥103.02B

  • Shares Out

    2,911.93M

  • Revenue

    CN¥38.71B

  • Employees

    38,134

Margins

  • Gross

    40.77%

  • EBITDA

    31.47%

  • Operating

    26.02%

  • Pre-Tax

    27.09%

  • Net

    22.04%

  • FCF

    21.04%

Returns (5Yr Avg)

  • ROA

    10.97%

  • ROTA

    16.29%

  • ROE

    15.66%

  • ROCE

    14.89%

  • ROIC

    13.56%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    CN¥58.36

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    CN¥14.67B

  • Net Debt

    -CN¥7,505.93M

  • Debt/Equity

    0.13

  • EBIT/Interest

    45.49

Growth (CAGR)

  • Rev 3Yr

    24.96%

  • Rev 5Yr

    28.38%

  • Rev 10Yr

  • Dil EPS 3Yr

    29.05%

  • Dil EPS 5Yr

    30.14%

  • Dil EPS 10Yr

  • Rev Fwd 2Yr

    3.62%

  • EBITDA Fwd 2Yr

    4.65%

  • EPS Fwd 2Yr

    6.93%

  • EPS LT Growth Est

    6.45%

Dividends

  • Yield

  • Payout

    33.89%

  • DPS

    CN¥0.99

  • DPS Growth 3Yr

    48.46%

  • DPS Growth 5Yr

    32.04%

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

    3.39%

SHSE:603259